패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Medartis Holding AG는 10명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
null null	Research Partners AG
Alexander Burgansky	Research Partners AG
null null	Stifel, Equities Research

Medartis Holding 배당 및 자사주 매입

배당 기준 점검 0/6

핵심 정보

최근 배당 및 자사주 매입 업데이트

Recent updates

Estimating The Intrinsic Value Of Medartis Holding AG (VTX:MED)

Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet

First half 2025 earnings released: CHF0.12 loss per share (vs CHF0.21 profit in 1H 2024)

Earnings Update: Medartis Holding AG (VTX:MED) Just Reported And Analysts Are Trimming Their Forecasts

Investors Continue Waiting On Sidelines For Medartis Holding AG (VTX:MED)

New minor risk - Share price stability

Medartis Holding AG (SWX:MED) entered into an agreement to acquire remaining 53% stake in KeriMedical SA for CHF 99 million.

New minor risk - Share price stability

Consensus EPS estimates fall by 17%

Consensus EPS estimates increase by 21%, revenue downgraded

Returns At Medartis Holding (VTX:MED) Appear To Be Weighed Down

Medartis Holding AG to Report Fiscal Year 2025 Results on Mar 17, 2026

We Think Medartis Holding's (VTX:MED) Robust Earnings Are Conservative

New CEO And Keri Touch Launch Will Accelerate US And LATAM Expansion

New minor risk - Earnings quality

These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well

Full year 2024 earnings: EPS and revenues miss analyst expectations

Medartis Holding AG to Report First Half, 2025 Results on Aug 19, 2025

Price target decreased by 11% to CHF91.13

Consensus EPS estimates increase by 16%, revenue downgraded

Even With A 29% Surge, Cautious Investors Are Not Rewarding Medartis Holding AG's (VTX:MED) Performance Completely

New major risk - Share price stability

A Piece Of The Puzzle Missing From Medartis Holding AG's (VTX:MED) Share Price

Medartis Holding (VTX:MED) Has A Rock Solid Balance Sheet

The Strong Earnings Posted By Medartis Holding (VTX:MED) Are A Good Indication Of The Strength Of The Business

First half 2024 earnings released: EPS: CHF0.19 (vs CHF0.07 loss in 1H 2023)

Medartis Holding AG (VTX:MED) Doing What It Can To Lift Shares

Medartis Holding AG to Report Fiscal Year 2024 Results on Mar 18, 2025

When Should You Buy Medartis Holding AG (VTX:MED)?

Consensus EPS estimates increase by 12%

Medartis Holding AG to Report First Half, 2024 Results on Aug 20, 2024

Shareholders Will Probably Not Have Any Issues With Medartis Holding AG's (VTX:MED) CEO Compensation

New minor risk - Shareholder dilution

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: CHF0.05 (vs CHF0.49 loss in FY 2022)

Now 20% overvalued

New major risk - Share price stability

The Returns On Capital At Medartis Holding (VTX:MED) Don't Inspire Confidence

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Is Medartis Holding (VTX:MED) A Risky Investment?

Price target increased by 20% to CHF133

Is Medartis Holding AG (VTX:MED) Expensive For A Reason? A Look At Its Intrinsic Value

First half 2023 earnings released: CHF0.07 loss per share (vs CHF0 in 1H 2022)

Medartis Holding AG, Annual General Meeting, Apr 17, 2024

Price target decreased by 13% to CHF110

Market Still Lacking Some Conviction On Medartis Holding AG (VTX:MED)

Price target decreased by 9.4% to CHF119

Full year 2022 earnings: EPS and revenues miss analyst expectations

Medartis Holding (VTX:MED) May Have Issues Allocating Its Capital

Less than half of directors are independent

Why Medartis Holding AG (VTX:MED) Could Be Worth Watching

Now 23% undervalued after recent price drop

These Analysts Think Medartis Holding AG's (VTX:MED) Sales Are Under Threat

First half 2022 earnings released: EPS: CHF0 (vs CHF0.60 in 1H 2021)

Medartis Holding AG, Annual General Meeting, Apr 21, 2023

Now 23% undervalued after recent price drop

When Should You Buy Medartis Holding AG (VTX:MED)?

Now 21% undervalued after recent price drop

Consensus forecasts updated

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

Medartis Holding AG (SWX:MED) completed the acquisition of Nextremity Solutions, Inc.

Less than half of directors are independent

Medartis Holding AG Announces Executive Changes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Medartis Holding AG Provides Sales Guidance for the Year 2022

At CHF123, Is It Time To Put Medartis Holding AG (VTX:MED) On Your Watch List?

Medartis Holding (VTX:MED) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to CHF120

We Think Medartis Holding (VTX:MED) Can Stay On Top Of Its Debt

Medartis Holding (VTX:MED) Could Be Struggling To Allocate Capital

First half 2021 earnings released: EPS CHF0.60 (vs CHF0.50 loss in 1H 2020)

Some Investors May Be Worried About Medartis Holding's (VTX:MED) Returns On Capital

How Much Of Medartis Holding AG (VTX:MED) Do Insiders Own?

Revenue and earnings miss expectations

Full year 2020 earnings released: CHF0.08 loss per share (vs CHF0.18 profit in FY 2019)